Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

O. Hrusak, V. de Haas, J. Stancikova, B. Vakrmanova, I. Janotova, E. Mejstrikova, V. Capek, J. Trka, M. Zaliova, A. Luks, K. Bleckmann, A. Möricke, J. Irving, B. Konatkowska, TB. Alexander, H. Inaba, K. Schmiegelow, S. Stokley, Z. Zemanova, AV....

. 2018 ; 132 (3) : 264-276. [pub] 20180502

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035270

Grantová podpora
NV15-28525A MZ0 CEP - Centrální evidence projektů

Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2% and 50% ± 12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5-year EFS of CD19+ leukemia was 83% ± 5.3% on ALL-type primary treatment compared with 0% ± 0% and 28% ± 14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using World Health Organization and/or European Group for Immunophenotyping of Leukemia definitions) and bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19+ ALAL. AML-type treatment is preferred in a minority of ALAL cases with CD19- and no other lymphoid features. No overall benefit of transplantation was documented, and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change in treatment type, this is to be considered only in cases with ≥5% blasts after remission induction. The results provide a basis for a prospective trial.

1st Department of Pediatrics University of Athens Athens Greece

Bioinformatics Centre 2nd Faculty of Medicine Charles University Prague Czech Republic

Center of Children's Oncohematology and BMT National Children's Specialized Hospital OHMATDYT Kiev Ukraine

Center of Oncocytogenetics Institute of Medical Biochemistry and Laboratory Diagnostics General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

Childhood Leukemia Investigation Prague Prague Czech Republic Department of Pediatric Hematology Oncology Charles University 2nd Faculty of Medicine Hospital Motol Prague Czech Republic

Comenius University Children's Hospital Bratislava Slovakia

Department of Oncology St Jude Children's Research Hospital Memphis TN

Department of Pathology St Jude Children's Research Hospital Memphis TN

Department of Pediatric Hematology Oncology Aghia Sophia Children's Hospital Athens Greece

Department of Pediatric Hematology Oncology and Transplantology University of Medical Sciences Poznan Poland

Department of Pediatric Hematology Oncology Charles University 2nd Faculty of Medicine Hospital Motol Prague Czech Republic

Department of Pediatrics Medical University of Vienna St Anna Children's Hospital and Children's Cancer Research Institute Vienna Austria

Dutch Childhood Oncology Group The Hague The Netherlands Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Helios Klinikum Berlin Buch Berlin Germany

Hematology and Oncology Hospital Nacional de Pediatría Prof Dr J P Garrahan Buenos Aires Argentina

Immunology and Rheumatology and

Institute of Medicine Faculty of Medicine University of Copenhagen Copenhagen Denmark

Laboratory of Pediatric Oncohematology Department of Woman's and Child's Health University of Padova Padova Italy

National Program for Antineoplastic Drugs for Children Chilean National Pediatric Oncology Group Hospital Roberto del Rio Universidad de Chile Santiago Chile Hospital del Salvador Universidad de Chile Santiago Chile

Nordic Society for Pediatric Hematology and Oncology Department of Pediatrics and Adolescent Medicine The Juliane Marie Centre Rigshospitalet Copenhagen University Hospital Copenhagen Denmark Institute of Medicine Faculty of Medicine University of Copenhagen Copenhagen Denmark

Northern Institute for Cancer Research Newcastle University Newcastle upon Tyne United Kingdom

Nottingham University Hospitals NHS Trust Nottingham United Kingdom

Pediatric Hematology and Oncology University Children's Hospital Essen Essen Germany

Pediatric Hematology Oncology Baylor College of Medicine Houston TX

Pediatric Hematology Oncology Schneider Children's Medical Center Petah Tikva Israel

Pediatrics Department Faculty of Medicine Federal University of Rio de Janeiro Rio de Janeiro Brazil

Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Sydney Children's Hospital Network Westmead NSW Australia

University Medical Center Christian Albrechts University Kiel Kiel Germany Department of Pediatrics University Medical Center Schleswig Holstein Campus Kiel Kiel Germany

000      
00000naa a2200000 a 4500
001      
bmc19035270
003      
CZ-PrNML
005      
20201022094940.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2017-12-821363 $2 doi
035    __
$a (PubMed)29720486
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hrusak, Ondrej $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
245    10
$a International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia / $c O. Hrusak, V. de Haas, J. Stancikova, B. Vakrmanova, I. Janotova, E. Mejstrikova, V. Capek, J. Trka, M. Zaliova, A. Luks, K. Bleckmann, A. Möricke, J. Irving, B. Konatkowska, TB. Alexander, H. Inaba, K. Schmiegelow, S. Stokley, Z. Zemanova, AV. Moorman, JG. Rossi, MS. Felice, L. Dalla-Pozza, J. Morales, M. Dworzak, B. Buldini, G. Basso, M. Campbell, ME. Cabrera, N. Marinov, S. Elitzur, S. Izraeli, D. Luria, T. Feuerstein, A. Kolenova, P. Svec, O. Kreminska, KR. Rabin, S. Polychronopoulou, E. da Costa, HV. Marquart, A. Kattamis, R. Ratei, D. Reinhardt, JK. Choi, M. Schrappe, J. Stary,
520    9_
$a Despite attempts to improve the definitions of ambiguous lineage leukemia (ALAL) during the last 2 decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study (International Berlin-Frankfurt-Münster Study of Leukemias of Ambiguous Lineage [iBFM-AMBI2012]) of 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (EFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80% ± 4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatment (36% ± 7.2% and 50% ± 12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5-year EFS of CD19+ leukemia was 83% ± 5.3% on ALL-type primary treatment compared with 0% ± 0% and 28% ± 14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using World Health Organization and/or European Group for Immunophenotyping of Leukemia definitions) and bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19+ ALAL. AML-type treatment is preferred in a minority of ALAL cases with CD19- and no other lymphoid features. No overall benefit of transplantation was documented, and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change in treatment type, this is to be considered only in cases with ≥5% blasts after remission induction. The results provide a basis for a prospective trial.
650    _2
$a mladiství $7 D000293
650    _2
$a biologické markery $7 D015415
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a management nemoci $7 D019468
650    _2
$a náchylnost k nemoci $7 D004198
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a akutní bifenotypická leukemie $x diagnóza $x etiologie $x terapie $7 D015456
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a de Haas, Valerie $u Dutch Childhood Oncology Group, The Hague, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
700    1_
$a Stancikova, Jitka $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Vakrmanova, Barbora $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Janotova, Iveta $u Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Mejstrikova, Ester $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Capek, Vaclav $u Bioinformatics Centre, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Trka, Jan $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Zaliova, Marketa $u Childhood Leukemia Investigation Prague, Prague, Czech Republic. Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Luks, Ales $u Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
700    1_
$a Bleckmann, Kirsten $u University Medical Center, Christian Albrechts University Kiel, Kiel, Germany. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Möricke, Anja $u University Medical Center, Christian Albrechts University Kiel, Kiel, Germany. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Irving, Julie $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
700    1_
$a Konatkowska, Benigna $u Department of Pediatric Hematology, Oncology and Transplantology, University of Medical Sciences, Poznan, Poland.
700    1_
$a Alexander, Thomas B $u Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Inaba, Hiroto $u Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Schmiegelow, Kjeld $u Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Institute of Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Stokley, Simone $u Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
700    1_
$a Zemanova, Zuzana $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Moorman, Anthony V $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
700    1_
$a Rossi, Jorge Gabriel $u Immunology and Rheumatology and.
700    1_
$a Felice, Maria Sara $u Hematology and Oncology, Hospital Nacional de Pediatría Prof. Dr. J. P. Garrahan, Buenos Aires, Argentina.
700    1_
$a Dalla-Pozza, Luciano $u Sydney Children's Hospital Network, Westmead, NSW, Australia.
700    1_
$a Morales, Jessa $u Sydney Children's Hospital Network, Westmead, NSW, Australia.
700    1_
$a Dworzak, Michael $u Department of Pediatrics, Medical University of Vienna, St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna, Austria.
700    1_
$a Buldini, Barbara $u Laboratory of Pediatric Oncohematology, Department of Woman's and Child's Health, University of Padova, Padova, Italy.
700    1_
$a Basso, Giuseppe $u Laboratory of Pediatric Oncohematology, Department of Woman's and Child's Health, University of Padova, Padova, Italy.
700    1_
$a Campbell, Myriam $u National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile. Hospital del Salvador, Universidad de Chile, Santiago, Chile.
700    1_
$a Cabrera, Maria Elena $u National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile. Hospital del Salvador, Universidad de Chile, Santiago, Chile.
700    1_
$a Marinov, Neda $u National Program for Antineoplastic Drugs for Children (PINDA), Chilean National Pediatric Oncology Group, Hospital Roberto del Rio/Universidad de Chile, Santiago, Chile. Hospital del Salvador, Universidad de Chile, Santiago, Chile.
700    1_
$a Elitzur, Sarah $u Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel.
700    1_
$a Izraeli, Shai $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Luria, Drorit $u Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel.
700    1_
$a Feuerstein, Tamar $u Pediatric Hematology Oncology, Schneider Children's Medical Center, Petah-Tikva, Israel.
700    1_
$a Kolenova, Alexandra $u Comenius University Children's Hospital, Bratislava, Slovakia.
700    1_
$a Svec, Peter $u Comenius University Children's Hospital, Bratislava, Slovakia.
700    1_
$a Kreminska, Olena $u Center of Children's Oncohematology and BMT, National Children's Specialized Hospital "OHMATDYT," Kiev, Ukraine.
700    1_
$a Rabin, Karen R $u Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX.
700    1_
$a Polychronopoulou, Sophia $u Department of Pediatric Hematology/Oncology, "Aghia Sophia" Children's Hospital, Athens, Greece.
700    1_
$a da Costa, Elaine $u Pediatrics Department, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
700    1_
$a Marquart, Hanne Vibeke $u Institute of Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Kattamis, Antonis $u First Department of Pediatrics, University of Athens, Athens, Greece.
700    1_
$a Ratei, Richard $u Helios Klinikum Berlin Buch, Berlin, Germany.
700    1_
$a Reinhardt, Dirk $u Pediatric Hematology and Oncology, University Children's Hospital Essen, Essen, Germany; and.
700    1_
$a Choi, John K $u Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Schrappe, Martin $u University Medical Center, Christian Albrechts University Kiel, Kiel, Germany. Department of Pediatrics, University Medical Center Schleswig Holstein, Campus Kiel, Kiel, Germany.
700    1_
$a Stary, Jan $u Department of Pediatric Hematology/Oncology, Charles University, Second Faculty of Medicine, Hospital Motol, Prague, Czech Republic.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 132, č. 3 (2018), s. 264-276
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29720486 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20201022094937 $b ABA008
999    __
$a ok $b bmc $g 1451930 $s 1073820
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 132 $c 3 $d 264-276 $e 20180502 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a NV15-28525A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace